Bayer’s woes with the Indian legal system are far from over. In 2011, the pharmaceutical company filed a suit to restrain India-based generic maker Natco from making, importing, selling or offering for sale cancer treatment drug sorafenib, sorafenib tosylate or any other generic version.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Mohan Dewan, R K Dewan & Co, India, Indian patent controller, Natco, patent, Bayer, Alembic Pharmaceuticals, section 107A, compulsory licence,
